AR083785A1 - Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) - Google Patents
Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a)Info
- Publication number
- AR083785A1 AR083785A1 ARP110104149A ARP110104149A AR083785A1 AR 083785 A1 AR083785 A1 AR 083785A1 AR P110104149 A ARP110104149 A AR P110104149A AR P110104149 A ARP110104149 A AR P110104149A AR 083785 A1 AR083785 A1 AR 083785A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- tl1a
- league
- antibodies against
- necrosis factor
- Prior art date
Links
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 title abstract 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 title abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 2
- 102000003390 tumor necrosis factor Human genes 0.000 title 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000009285 allergic inflammation Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000037903 inflammatory enteropathy Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Acido nucleico que lo codifica, composición farmacéutica. Los anticuerpos anti-hTL1A humanos son útiles para tratar enfermedades o trastornos asociados al TL1A, tales como enfermedades o trastornos inflamatorios, tales como enteropatías inflamatorias, que incluyen colitis ulcerosa y enfermedad de Crohn, artritis reumatoide y similares; enfermedades o trastornos autoinmunitarios, tales como esclerosis múltiple, diabetes y similares; y reacciones alérgicas, tales como el asma y la inflamación alérgica del pulmón.Reivindicación 1: Anticuerpo humano aislado o fragmento de unión al antígeno que se une específicamente y neutraliza la actividad del ligando 1A de tipo TNF humano (hTL1A).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41127610P | 2010-11-08 | 2010-11-08 | |
| US201161478309P | 2011-04-22 | 2011-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083785A1 true AR083785A1 (es) | 2013-03-20 |
Family
ID=45002143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104149A AR083785A1 (es) | 2010-11-08 | 2011-11-07 | Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8642741B2 (es) |
| EP (1) | EP2638069B1 (es) |
| JP (2) | JP6076911B2 (es) |
| KR (1) | KR101896129B1 (es) |
| CN (1) | CN103261228B (es) |
| AR (1) | AR083785A1 (es) |
| AU (1) | AU2011326097B2 (es) |
| BR (1) | BR112013011245A2 (es) |
| CA (1) | CA2816799C (es) |
| CL (1) | CL2013001279A1 (es) |
| EA (1) | EA030397B1 (es) |
| IL (1) | IL226172A (es) |
| JO (1) | JO3375B1 (es) |
| MX (1) | MX355580B (es) |
| MY (1) | MY185006A (es) |
| NZ (2) | NZ610294A (es) |
| PH (1) | PH12013500912A1 (es) |
| SG (2) | SG10201504265RA (es) |
| TW (1) | TWI606118B (es) |
| UY (1) | UY33715A (es) |
| WO (1) | WO2012064682A1 (es) |
| ZA (1) | ZA201304114B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| DK2564695T3 (en) | 2009-07-08 | 2015-05-26 | Kymab Ltd | Animal models and therapeutic molecules |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| KR101982899B1 (ko) * | 2011-09-30 | 2019-05-27 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | ＴＬ1ａ에 대한 항체 및 그의 용도 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JP2016502520A (ja) | 2012-11-13 | 2016-01-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗プロキネチシン受容体（ｐｒｏｋｒ）抗体およびその使用 |
| CN105102067B (zh) * | 2013-01-02 | 2020-03-03 | 艾科诺斯科技股份有限公司 | 结合tl1a的抗体及其用途 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| BR112015024752A2 (pt) | 2013-03-27 | 2017-07-18 | Cedars Sinai Medical Center | mitigação e reversão da fibrose e inflamação através da inibição da função de tl1a e vias de sinalização relacionadas |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| AU2014348676B2 (en) * | 2013-11-13 | 2020-06-18 | Bristol-Myers Squibb Company | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
| US10160805B2 (en) | 2014-07-11 | 2018-12-25 | New York University | Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody |
| WO2016077720A1 (en) * | 2014-11-14 | 2016-05-19 | Protein One, Llc | Binding agents and uses thereof |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| US20180319889A1 (en) * | 2015-11-02 | 2018-11-08 | La Jolla Institute For Allergy & Immunology | Method and medicament for treating airway and/or lung diseases |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| JP7082945B2 (ja) * | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| BR112018072211A2 (pt) | 2016-05-09 | 2019-02-12 | Bristol-Myers Squibb Company | anticorpos anti tl1a e utilizações dos mesmos |
| WO2018081074A1 (en) | 2016-10-26 | 2018-05-03 | Cedars-Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| US11426706B2 (en) | 2017-06-21 | 2022-08-30 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
| JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| RU2689522C1 (ru) * | 2018-09-11 | 2019-05-28 | Общество с ограниченной ответственностью "Пальмира Биофарма" | Нуклеотидная последовательность, кодирующая слитый белок, состоящий из растворимого внеклеточного домена человеческого tnfr1 и константной части тяжёлой цепи человеческого igg4 |
| WO2020112890A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| IL292419A (en) | 2019-10-24 | 2022-06-01 | Prometheus Biosciences Inc | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| US20230287499A1 (en) * | 2020-06-03 | 2023-09-14 | Cedars-Sinai Medical Center | Methods and systems for measuring post-operative disease recurrence |
| US20240309104A1 (en) * | 2021-02-18 | 2024-09-19 | Prometheus Biosciences, Inc. | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| CA3207818A1 (en) * | 2021-02-18 | 2022-08-25 | Allison LUO | Anti-tl1a antibody compositions and methods of treatment in the lung |
| AU2024273758A1 (en) | 2023-05-17 | 2025-12-04 | Genentech, Inc. | Anti-tl1a antibody therapeutic methods |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
| US20250109209A1 (en) | 2023-10-03 | 2025-04-03 | Absci Corporation | Tl1a associated antibody compositions and methods of use |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| CN120530139A (zh) * | 2023-12-29 | 2025-08-22 | 成都优洛生物科技有限公司 | 抗tl1a抗体或其抗原结合片段及应用 |
| JP2025115976A (ja) * | 2024-01-26 | 2025-08-07 | フューチャージェン・バイオファーマシューティカル（ベイジン）カンパニー・リミテッド | Ｔｌ１ａに特異的に結合できる抗体及びその使用 |
| CN120424214A (zh) * | 2024-02-05 | 2025-08-05 | 三生国健药业（上海）股份有限公司 | 一种抗tl1a抗体及其制备方法和用途 |
| CN120818053A (zh) * | 2024-04-11 | 2025-10-21 | 北京伟德杰生物科技有限公司 | Tl1a抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US7820798B2 (en) | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| JP2003506088A (ja) * | 1999-08-04 | 2003-02-18 | アムジェン インコーポレーテッド | ＴＮＦリガンドスーパー遺伝子ファミリーの新規のメンバーであるＦｈｍ |
| US7378091B2 (en) * | 2001-12-03 | 2008-05-27 | Amgen Fremont Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| ES2428321T3 (es) * | 2003-08-20 | 2013-11-07 | University Of Miami | Composiciones y métodos para tratar la enfermedad del pulmón inflamado |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US20090317388A1 (en) * | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
| ES2611307T3 (es) * | 2005-08-30 | 2017-05-08 | University Of Miami | Inmunomodulación de agonistas, antagonistas e inmunotoxinas del receptor del factor de necrosis tumoral 25 (TNFR25) |
| MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| JP2010534469A (ja) * | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | Ｋｄｒ指向性標的化結合物質およびその使用 |
| NZ585559A (en) * | 2007-11-13 | 2012-11-30 | Teva Biopharmaceuticals Usa Inc | Humanized antibodies against tl1a |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
-
2011
- 2011-10-31 JO JOP/2011/0327A patent/JO3375B1/ar active
- 2011-11-07 TW TW100140461A patent/TWI606118B/zh not_active IP Right Cessation
- 2011-11-07 AR ARP110104149A patent/AR083785A1/es unknown
- 2011-11-08 NZ NZ610294A patent/NZ610294A/en not_active IP Right Cessation
- 2011-11-08 WO PCT/US2011/059675 patent/WO2012064682A1/en not_active Ceased
- 2011-11-08 EP EP11785543.7A patent/EP2638069B1/en active Active
- 2011-11-08 MX MX2013005141A patent/MX355580B/es active IP Right Grant
- 2011-11-08 CA CA2816799A patent/CA2816799C/en active Active
- 2011-11-08 SG SG10201504265RA patent/SG10201504265RA/en unknown
- 2011-11-08 US US13/291,145 patent/US8642741B2/en active Active
- 2011-11-08 CN CN201180059396.1A patent/CN103261228B/zh active Active
- 2011-11-08 AU AU2011326097A patent/AU2011326097B2/en not_active Ceased
- 2011-11-08 MY MYPI2013700737A patent/MY185006A/en unknown
- 2011-11-08 PH PH1/2013/500912A patent/PH12013500912A1/en unknown
- 2011-11-08 UY UY0001033715A patent/UY33715A/es unknown
- 2011-11-08 SG SG2013034764A patent/SG190176A1/en unknown
- 2011-11-08 NZ NZ706986A patent/NZ706986A/en not_active IP Right Cessation
- 2011-11-08 BR BR112013011245-0A patent/BR112013011245A2/pt not_active Application Discontinuation
- 2011-11-08 KR KR1020137014739A patent/KR101896129B1/ko active Active
- 2011-11-08 JP JP2013537924A patent/JP6076911B2/ja active Active
- 2011-11-08 EA EA201370105A patent/EA030397B1/ru unknown
-
2013
- 2013-05-05 IL IL226172A patent/IL226172A/en active IP Right Grant
- 2013-05-08 CL CL2013001279A patent/CL2013001279A1/es unknown
- 2013-06-05 ZA ZA2013/04114A patent/ZA201304114B/en unknown
- 2013-12-31 US US14/144,800 patent/US9556277B2/en active Active
-
2016
- 2016-09-12 JP JP2016177515A patent/JP6272970B2/ja active Active
- 2016-12-15 US US15/380,696 patent/US20170096491A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083785A1 (es) | Anticuerpos humanos contra el ligando 1a de tipo tnf (factor de necrosis tumoral) humano (tl1a) | |
| PE20130646A1 (es) | Anticuerpos antagonistas anti receptor de il-7 y procedimientos | |
| MX2025007735A (es) | Anticuerpos anti-il36r | |
| UA115540C2 (uk) | Антитіло до il-36r | |
| EA201590412A1 (ru) | Композиции антител и их применения | |
| PH12012501761A1 (en) | Anti-nerve growth factor (ngf) antibody compositions | |
| MX2014001370A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| MX388027B (es) | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. | |
| MX348578B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| CL2011002744A1 (es) | Anticuerpo anti il-17f monoclonal; composicion farmaceutica; uso de dicho anticuerpo para artritis reumatoide, enfermedad de crohn, psoriasis, esclerosis multiple, enfermedad pulmonar obstructiva cronica o asma en un sujeto. | |
| PH12015501994B1 (en) | Antibodies that bind il-23 | |
| UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
| IN2014DN08025A (es) | ||
| PE20190440A1 (es) | Anticuerpos a la alfa-sinucleina y usos de los mismos | |
| CL2013001290A1 (es) | Anticuerpo aislado, o su fragmento, que se une a beta secretasa (bace1); acido nucleico que codifica el anticuerpo; celula huesped que comprende el acido nucleico; metodo para producir un anticuerpo; inmunoconjugado que comprende el anticuerpo; formulacion farmaceutica; uso del anticuerpo para tratar enfermedad o trastorno neurológico. | |
| UA118646C2 (uk) | Виділене антитіло, яке специфіічно зв'язується з онкостатином м (оm) людини | |
| UA105405C2 (ru) | Гуманизированное антитело против человеческого il-22ra | |
| UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
| CR20150153A (es) | Tratamiento para artitris reumatoide | |
| WO2017014679A3 (en) | Humanized monoclonal antibody specific to syndecan-1 | |
| PE20170519A1 (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| FI3172232T3 (fi) | TREM-1-vasta-aineiden kohdennettu mutageneesi viskositeetin alentamista varten | |
| IN2014CN04652A (es) | ||
| EA201491957A1 (ru) | Антитела к ccl2 для лечения склеродермии | |
| MY176745A (en) | Method of treating a tl1a-associated disease or disorder with human antibodies to tl1a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |